TUCSON (Dec. 4, 2015) - Tucson based pharmaceutical company NuvOx Pharma announced today that it has secured orphan drug designation from the FDA for its investigational radiosensitizer for glioblastoma multiforme. Glioblastoma is the most prevalent and aggressive form of brain cancer. Over 10,000 new patients are diagnosed with glioblastoma in the U.S. each year. Despite advances in surgery, radiation, and chemotherapy, recurrence is almost a certainty, occurring on average in less than a year. Survival is poor and fewer than 10% of these patients live more than five years.
TUCSON (Nov. 30, 2015) - Evan Unger, MD, President and CEO of NuvOx, said, “We are pleased to announce that our platform technology oxygen therapeutic has shown pharmacodynamic effects in our Phase 1b clinical trial in Glioblastoma multiforme (GBM). We are observing radiation sensitizing pharmacodynamics effects that have presumed therapeutic efficacy. We are confirming this with the addition of 3 additional patients at the dose of 0.1 cc/kg of NVX-108. Read More
TUCSON (July 11, 2015) - Evan Unger, President and CEO of NuvOx, announced today that Mike Sember, will join the Board of Directors of NuvOx Pharma. Mike has more than 40 years of comprehensive experience working with public and private pharmaceutical, biotech and medical device companies in the U.S. and Europe. Read More
PHOENIX (July 6, 2015) -
There is a new weapon in the arsenal of radiation-resistant tumor treatments, and a Tucson-based biotechnology company is determined to wipe them out.
NuvOx Pharma has developed a breakthrough nanotechnology that can infuse tumors with oxygen so they become more susceptible to radiation therapy. The technology uses an injected compound that delivers 200 times more oxygen to the body compared to hemoglobin. Read More
TUCSON (June 28, 2015) - NuvOx Pharma has completed a licensing agreement with the University of Pittsburgh for a patent application entitled, “Treatment of Acute Complications of Sickle Cell Disease.” Inventors on the patent are Evan Unger, MD, David Wilson, PhD, both from NuvOx, and Solomon Ofori-Acquah, PhD, from the University of Pittsburgh. Read More
PHOENIX (April 28, 2015) -
The Arizona Commerce Authority (ACA) today met with Dr. Evan Unger, Nuvox Pharma President and CEO to present him with the 2014 Arizona Innovation Challenge Award. Read More
To read more news about NuvOx Pharma, please visit our news page.
To view more NuvOx Pharma publications, please visit our publication page.
This is a comprehensive presentation of the company's Oxygen Nanotechnology Platform for treating life threatening conditions.
Dr. Unger has pioneered original research, championed the clinical translation of his research products, and founded companies in the technology-based private sector to market these products. Dr. Unger's products are routinely used in clinical diagnostic tests that impact the lives of Arizonans and improve healthcare world-wide.
NuvOx Pharma's CBO, David Wilson presents life saving innovation at AZBio Expo 2013
11th in a series of interviews from the ICUS Bubble Conference
Updated Cochrane review comparing types of toothbrushes finds some difference in the short-term. [...]
Reviewers from Finland's national medicines agency study medicated skin treatments and shampoo [...]
The latest from the updated Cochrane Collaboration systematic review on exercise for people with hea [...]
A review from the US Agency for Healthcare Quality and Research (AHRQ) analyzes evidence about speci [...]
An individual patient data meta-analysis analyzes CBT website impact on moderate versus mild depress [...]